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Cardiovascular (CV) disease is the major cause of death
in the general population and in chronic kidney disease
(CKD) patients. In particular, the CV morbidity and mor-
tality rate is highly prevalent in CKD patients because of
frequently concomitant hypertension, peripheral vascular
disease, heart failure, vascular calciﬁcation (VC), diabetes
and mineral bone disease (CKD-MBD). More recently, a
‘relatively’ new emerging factor that is strongly associ-
ated with CV risk in CKD patients has been recognized
and investigated: vitamin D deﬁciency [1].
Our understanding of the biological effects of the
vitamin D system has evolved considerably in recent
years, with the identiﬁcation of 25-hydroxyvitamin D (25-
D) and 1,25-dihydroxyvitamin D (1,25-D) as hormones
with ‘pleiotropic’ effects beyond mineral metabolism and
parathyroid hormone (PTH) control in CKD patients [2].
Indeed, recent studies have been proposed and realized
to investigate the effects of either native 25-D or active
1,25-D on the CV and renal systems [3].
I read with interest the article by Loh et al. [4] in this
issue of the journal regarding the association of lower
serum 25-D levels and the prevalence of diabetes and
absence of native vitamin D supplementation in 219 CKD
patients in Singapore. Considering that Singapore is a
country where exposure to sunlight is adequate, it may
be surprising to learn that 25.6% of the observed CKD
patients showed serum 25-D levels <16 ng/mL. As it is
nearly impossible to get adequate amounts of vitamin D
from their diet (mushrooms, eggs and ﬁsh), sunlight
exposure is the only reliable way to generate vitamin
D. Even in such a sun-rich country as Singapore, vitamin
D deﬁciency is high in CKD patients. Do we have a sol-
ution to this problem?
The ‘optimal’ vitamin D levels remain to be deter-
mined; however, the deﬁnition of ‘vitamin D deﬁciency’
when 25-D levels fall <20 ng/mL (∼50 nmol/L) should be
generally accepted.
Vitamin D receptors (VDRs) are present in several
(probably all) systems and tissues (Figure 1) and VDR
activation is associated with positive effects, such as
better blood pressure control and prevention of diabetic
nephropathy. Systemic activation of VDRs, as suggested
by observational studies, may decrease CV mortality in
the general population and especially in patients affected
by renal failure [5]. Moreover, a meta-analysis of random-
ized trials analysing the impact of vitamin D among
patients with different health conditions demonstrated
that vitamin D intake reduces the all-cause mortality
rates [6].
In a prospective study, men with vitamin D deﬁciency
(25-D levels <15 ng/mL) showed an increased risk of myo-
cardial infarction [5]: it was proposed that VDR signalling
had a possible anti-hypertrophic action. Vitamin D
deﬁciency was also found to be associated with an in-
creased pulse wave velocity and arterial stiffness along
with increased left ventricular hypertrophy and CV mor-
tality in dialysis patients [7, 8]. Some clinical studies
showed an inverse relationship between the circulating
vitamin D levels and blood pressure and/or plasma renin
activity, but the mechanism is unclear [9].
Nevertheless, CKD patients present a condition of
chronic inﬂammation involving the CV system and a
reduced immunity to infections. Evidence from several
studies demonstrated a possible role of vitamin D as an
immuno-modulatory and anti-inﬂammatory agent [10].
Non-speciﬁc microinﬂammation, characterizing CKD
patients, has been investigated as a risk factor involved
in the pathogenesis of accelerated atherosclerosis and
VC. In fact, CKD patients affected by vascular or valvular
calciﬁcation have higher serum levels of various markers
of inﬂammation, such as C-reactive protein and tumor
necrosis factor (TNF)-α or interleukin-6 (IL-6) [11].
The link between vitamin D deﬁciency and CV morbid-
ity and mortality is currently arousing great interest. In
CKD patients, this association is even stronger, because
VDR activation decreases as a result of progressive renal
impairment. In fact, a poor vitamin D status in CKD
patients is a risk factor for CV mortality. Haemodialysis
patients with very low levels of 25-D and 1,25-D are at a
signiﬁcantly increased risk of early CV mortality, including
sudden cardiac arrest [12, 13]. Furthermore, in non-
dialysis CKD patients this increased risk still persists with
severely deﬁcient 25-D levels <10 ng/mL showing an
almost 6-fold higher risk of mortality than patients with
adequate levels (≥30 ng/mL) [14].
Most importantly, native vitamin D supplementation
with ergocalciferol or cholecalciferol has been associated
with a signiﬁcant reduction in total mortality by 7% com-
pared with placebo [6]. Therefore, accordingly with the
Kidney Disease: Improving Global Outcome guidelines
25-D testing should be routine in CKD patients and they
should be re-tested after 3 months of supplementation,
aiming for a level of at least 30 ng/mL [15].
Although native (or dietary) vitamin D supplementation
can replenish 25-D levels in CKD, there is also a need for
VDR activation therapy (calcitriol or selective VDR activa-
tors) to correct abnormally low levels of 1,25-D and to
control serum PTH levels [16, 17].
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In conclusion, because the CV system is a major target
tissue for vitamin D, CKD patients with a poor 25-D status
are at elevated risk of CV mortality [18]. Native vitamin D
may reduce CV events and mortality, even if, at present,
no sufﬁcient outcome data can conﬁrm this. Large ran-
domized controlled trials should elucidate this apparent
beneﬁt of CV risk reduction and mortality in CKD patients
treated with vitamin D.
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(See related article by Loh et al. Clinical and demographic
predictors for vitamin D deﬁciency in multiethnic Asian
patients with chronic kidney disease. Clin Kidney J 2012;
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